| アブストラクト | Proton pump inhibitors, PPIs, are widely prescribed and sold globally. Although initially intended for time-limited treatment of acute disorders, such as gastric ulcers and esophagitis, PPIs are now commonly used for prolonged durations and are considered safe for over the counter access. Recent studies have raised concern over associations between PPI use and acute kidney injury, chronic kidney disease, end-stage renal disease, and electrolyte abnormalities. The growing concern over potentially serious adverse drug reactions warrants an evaluation of post marketing surveillance data. In this study of over ten million FDA Adverse Event Reporting System records, we provided evidence of kidney injury and electrolyte imbalances in an alarming number of patients taking PPIs. Additionally, we assessed differences between specific PPIs and observed significant electrolyte and renal abnormalities for each individual drug with varying magnitudes. |
|---|
| ジャーナル名 | Scientific reports |
|---|
| Pubmed追加日 | 2019/2/21 |
|---|
| 投稿者 | Makunts, Tigran; Cohen, Isaac V; Awdishu, Linda; Abagyan, Ruben |
|---|
| 組織名 | Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California,;San Diego, La Jolla, CA, 92093-0747, USA.;San Diego, La Jolla, CA, 92093-0747, USA. ruben@ucsd.edu. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/30783195/ |
|---|
